The data will be summarised in the CSR and the final report included as an appendix . 5.13.2 Secondary endpoint s 5.13.2.1 Identification of peptide specific T cells (Secondary Immunogenicity Endpoint Population) Immunological response will be measured in whole blood (PBMCs) by hTERT specific T cells as measured by ELISPOT analysis at the following time points: • baseline, • vaccination weeks 3, 4 and 6, • 2 weeks post last vaccination and • 3, 6 and 12 months post firs t vaccination. Vaccine induced ELISPOT response in blood will be reported longitudinally for each patient. The total number of patients showing durable peripheral immune response, defined as a change in one validated assay at two time points after at least two vaccinations (where a change is defined as 2.5 fold change over baseline [ after removal of background ], assay control and >35 spots/10 6 cells) will be reported. Interim reports are expected at timepoints to be agreed between the Sponsor and the laboratory.